Skip to main content

Advertisement

SpringerLink
Log in

Oxaliplatin

A Review of its Use in the Management of Metastatic Colorectal Cancer

  • Adis Drug Evaluation
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Abstract

Oxaliplatin is a cytotoxic agent which, like other platinum compounds, acts primarily by causing inter- and intra-strand cross-links in DNA, thereby inhibiting DNA synthesis. Oxaliplatin has a bulky carrier ligand which is thought to enhance cytotoxicity and abolish cross-resistance between oxaliplatin and other platinum compounds.

Phase II and III clinical trials have found oxaliplatin combined with fluorouracil/calcium folinate (leucovorin/folinic acid) to be an effective first- and second-line treatment for patients with metastatic colorectal cancer. First-line triple therapy with oxaliplatin and fluorouracil/calcium folinate achieved significantly higher response rates than fluorouracil/calcium folinate alone in 2 phase III studies (objective response rates 59 vs 23% and 50.7 vs 22.3%). In addition, median progression-free survival was longer with triple therapy in both studies (8.9 vs 5.2 and 8.75 vs 6.0 months). However, there was no significant difference in median duration of survival between treatment groups, although this may be a consequence of the subsequent use of oxaliplatin and/or surgery in patients who relapsed during therapy with fluorouracil/calcium folinate alone.

About 30 to 45% of patients (whose disease progressed during or after fluorouracil-based therapy) responded to second-line combination therapy with oxaliplatin and fluorouracil/calcium folinate. Median progression-free survival ranged from 7 to 10 months and the median duration of survival from 10 to 17 months.

Objective responses were achieved in 20 and 24% of patients in 2 small trials of first-line oxaliplatin mono therapy and in about 10% of patients given the drug as a second-line option.

Peripheral sensory neuropathy is the dose-limiting toxicity associated with oxaliplatin. Severe neurotoxicity has been estimated to occur in 10% of patients after 6 treatment cycles and in 50% after 9 cycles of an oxaliplatin dosage of 130 mg/m2 once every 3 weeks. It is cumulative, but reversible on discontinuation of therapy. Nausea, vomiting and diarrhoea are common, but are usually mild to moderate. Myelosuppression is also observed, but is usually mild.

Conclusion: oxaliplatin is a promising treatment option for patients with metastatic colorectal cancer. It appears to be particularly advantageous (in terms of response rate and duration of progression-free survival) when used in combination with fluorouracil/calcium folinate as both a first- and second-line option, although preliminary studies have failed to show any survival advantage over fluorouracil/calcium folinate alone. Promising results have been found in studies of the drug as monotherapy, and oxaliplatin may also prove useful in the neoadjuvant setting in patients with unresectable liver metastases; however, data are limited at present.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Similar content being viewed by others

References

  1. Parker SL, Tong T, Bolden S, et al. Cancer Statistics, 1996. CA Cancer J Clin 1996; 46(1): 5–27

    Article  PubMed  CAS  Google Scholar 

  2. Cancer Research Campaign. Cancer Statistics Factsheet 1995; 3.2–3

    Google Scholar 

  3. van Triest B, van Groeningen CJ, Pinedo HM. Current chemo-therapeutic possibilities in the treatment of colorectal cancer. Eur J Cancer 1995; 31A: 1193–7

    Article  PubMed  Google Scholar 

  4. Connors TA, Duncan R, Knox RJ. The chemotherapy of colon cancer. Eur J Cancer 1995; 31ASuppl. A: 1373–8

    Article  PubMed  CAS  Google Scholar 

  5. Anon. Innovative drug for colorectal cancer now available in France. Anticancer Drugs 1996; 7: 131

    Article  Google Scholar 

  6. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994; 330: 1136–42

    Article  PubMed  CAS  Google Scholar 

  7. Poon MA, O’Connell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9: 1967–72

    PubMed  CAS  Google Scholar 

  8. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by folinic acid in patietns with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896–903

    Google Scholar 

  9. Ahlgren JD, Trocki O, Gullo JJ, et al. Protracted infusion of 5-FU with weekly low-dose cisplatin as second-line therapy in patients with metastatic colorectal cancer who have failed 5-FU monotherapy. Cancer Invest 1991; 9: 27–33

    Article  PubMed  CAS  Google Scholar 

  10. Bertrand M, Doroshow JH, Multhauf P, et al. High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study. J Clin Oncol 1986; 4Suppl.7: 1058–61

    PubMed  CAS  Google Scholar 

  11. DeLap R, Bodurian E, Nazzaro D, et al. PALA plus 5-FU in colorectal cancer: pilot clinical study of a convenient outpatient treatment regimen. Proc Am Assoc Cancer Res 1993; 34: 285

    Google Scholar 

  12. Izzo J, Cvitkovic E, Zarba J, et al. Low dose 5FU continuous infusion (FuCI) in advanced colorectal cancer (ACC): clinical evidence for reversal of acquired/intrinsic resistance to 5FU or 5FU folinic (FUF0). Ann Oncol 1992; 3Suppl. 5: 20

    Google Scholar 

  13. Leong L, Doroshow J, Akman S, et al. Phase II trial of 5-FU and high dose folinic acid (HDFA) with cisplatin (CDDP) and dipyridamole (DP) in advanced colorectal cancer [abstract no. 383]. Proc Am Soc Clin Oncol 1989; 8: 99

    Google Scholar 

  14. Wiseman LR, Markham A. Irinotecan: a review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996; 52: 606–23

    Article  PubMed  CAS  Google Scholar 

  15. Gunasekara NS, Faulds D. Raltitrexed: a review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1998; 55: 423–35

    Article  PubMed  CAS  Google Scholar 

  16. Clark JW. Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer. Semin Oncol 1997; 24Suppl. 18: 19–24

    Google Scholar 

  17. Misset JL, Chollet P, Vennin P, et al. Multicentric phase II-III trial of oxaliplatin versus cisplatin both in association with cyclophosphamide in the treatment of advanced ovarian cancer: toxicity efficacy results [abstract]. 33rd Proc Am Soc Clin Oncol 1997; 16: 354

    Google Scholar 

  18. Soulie P, Bensaine A, Garrino C, et al. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur J Cancer 1997; 33: 1400–6

    Article  PubMed  CAS  Google Scholar 

  19. Faivre S, Bourdon O, Bensmaine MA, et al. Paclitaxel/oxaliplatin association in pretreated recurrent ovarian carcinoma patients [abstract]. 33rd Proceedings of the American Society of Clinical Oncology (ASCO): 1997 May 17–20; Denver, 369

  20. Chollet P, Bensmaine MA, Brienza S, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 1996; 7: 1065–70

    Article  PubMed  CAS  Google Scholar 

  21. Garufi C, Nisticö C, Brienza S, et al. Oxaliplatin activity in anthracycline (ANT)-resistant metastatic breast cancer patients [abstract]. 33rd Proceedings of the American Society of Clinical Oncology (ASCO): 1997 May 17–20; Denver, 170

  22. Caussanel J-P, Lèvi F, Brienza S, et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990; 82: 1046–50

    Article  PubMed  CAS  Google Scholar 

  23. Monnet I, Brienza S, Hugret F, et al. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). Eur J Cancer A 1998; 34: 1124–7

    Article  PubMed  CAS  Google Scholar 

  24. Rotarski M, Brienza S, Gastiaburu J, et al. Oxaliplatin (L-OHP (Rm)): a new platinum analog: active in refractory/relapsed intermediate and low grade non-Hodgkin lymphoma: a phase I-II study [abstract]. Proc Am Soc Clin Oncol 1993; 12: 375

    Google Scholar 

  25. O’Dwyer PJ, Johnson SW, Hamilton TC. Cisplatin and its analogues. In: DeVita VTJ, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven, 1997: 418–32

    Google Scholar 

  26. Harstick A, Vanhoefer U, Seeber S. New drugs in colorectal cancer: a review of antitumor activity and cross-resistance patterns of topoisomerase I inhibitors, thymidylate synthetase inhibitors, and oxaliplatin. Onkologie 1998; 21: 95–103

    Article  Google Scholar 

  27. Saris CP, Vandevaart PJM, Rietbroek RC, et al. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 1996; 17: 2763–9

    Article  PubMed  CAS  Google Scholar 

  28. Woynarowski JM, Chapman WG, Napier C, et al. Oxaliplatin effects on naked and intracellular DNA [abstract]. 88th Annual Meeting of the American Association for Cancer Research (AACR): 1997 Apr 12–16; San Diego, 311

  29. Mamenta EL, Poma EE, Kaufmann WK, et al. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 1994; 54: 3500–5

    PubMed  CAS  Google Scholar 

  30. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute’s Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52: 1855–65

    Article  PubMed  CAS  Google Scholar 

  31. Schmidt W, Chaney SG. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 1993; 53: 799–805

    PubMed  CAS  Google Scholar 

  32. Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; 25 (2 Suppl. 5): 4–12

    PubMed  CAS  Google Scholar 

  33. El-akawi R, Abu-Hadid R, Perez R, et al. Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett 1996; 105: 5–14

    Article  PubMed  CAS  Google Scholar 

  34. El-akawi Z, Zdanowicz J, Creaven PJ, et al. Induction of glutamyl transpeptidase mRNA by platinum complexes in a human ovarian carcinoma cell line. Oncol Res 1996; 8: 425–34

    Google Scholar 

  35. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996; 56: 4881–6

    PubMed  CAS  Google Scholar 

  36. Kraker AJ, Moore CW. Accumulation of eis diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res 1988; 48: 9–13

    PubMed  CAS  Google Scholar 

  37. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993; 53: 5970–6

    PubMed  CAS  Google Scholar 

  38. Silvestro L, Anal H, Sommer F, et al. Comparative effects of a new platinum analog (trans- 1-diamine-cyclohexane oxalato-platinum; L’OHP) with CDDP on various cells: correlation with intracellular accumulation [abstract no. 115]. Anticancer Res 1990; 10: 1376

    Google Scholar 

  39. Riccardi A, Meco D, Lasorella A, et al. Comparison of cytotoxicity of oxaliplatin, cisplatin and carboplatin in human neuroblastoma (NB) cell lines [abstract]. Proc Am Soc Clin Oncol 1997; 16: 249

    Google Scholar 

  40. Pendyala L, Creaven PJ, Perez R, et al. Intracellularglutathione and cytotoxicity of platinum complexes. Cancer Chemother Pharmacol 1995; 36: 271–8

    Article  PubMed  CAS  Google Scholar 

  41. Perez RP, O’Dwyer PJ, Handel LM, et al. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines. Int J Cancer 1991; 48: 265–9

    Article  PubMed  CAS  Google Scholar 

  42. Dunn TA, Schmoll HJ, Grünwald V, et al. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs 1997; 15(2): 109–14

    Article  PubMed  CAS  Google Scholar 

  43. Fukuda M, Ohe Y, Kanzawa F, et al. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Anticancer Res 1995; 15: 393–8

    PubMed  CAS  Google Scholar 

  44. Raymond E, Lawrence R, Izbicka E, et al. Activity of oxaliplatin against human tumor colony-forming units. Clin Cancer Res 1998; 4: 1021–9

    PubMed  CAS  Google Scholar 

  45. Raymond E, Djelloul C, Buquet-Fagot F, et al. Oxaliplatin (LOHP) and cisplatin (CDDP) in combination with 5FU, specific thymidase synthase (TS) inhibitors (AG337, ZD1694), and topoisomerase I (Topo-I) inhibitors (SN38, CPT-11), in human colonic, ovarian and breast cancers [abstract no. 1981]. Proc Am Assoc Cancer Res 1996; 37: 291

    Google Scholar 

  46. Raymond E, Buquet-Fagot C, Djelloul S, et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997; 8: 876–85

    Article  PubMed  CAS  Google Scholar 

  47. Zeghari-Squalli N, Misset JL, Cvitkovic E, et al. Mechanism of the in vitro synergism between SN38 and oxaliplatin [abstract]. 88th Annu Meet Am Assoc Cancer Res 1997; 38: 3

    Google Scholar 

  48. Erlichman C, Boerner S, Kaufmann SH. Interactions of oxaliplatin with the topoisomerase I inhibitors toptecan and SN-38 [abstract no. 225]. Ann Oncol 1998; 9Suppl. 2: 59

    Google Scholar 

  49. Mathè G, Kidani Y, Noji M, et al. Antitumor activity of 1-OHP in mice. Cancer Lett 1985; 27: 135–43

    Article  PubMed  Google Scholar 

  50. Noji M, Okamoto K, Kidani Y, et al. Relation of conformation to antitumor activity of platinum(II) complexes of 1,2-cyclohexanediamine and 2-(aminomethyl)cyclohexylamine isomers against leukemia P388. J Med Chem 1981; 24: 508–15

    Article  PubMed  CAS  Google Scholar 

  51. Tashiro T, Kawada Y, Sakurai Y, et al. Antitumor activity of a new platinum complex, oxalato (/ranj-l-l,2-diaminocyclo-hexane) platinum (II): new experimental data. Biomed Pharmacother 1989; 43: 251–60

    Article  PubMed  CAS  Google Scholar 

  52. Mathè G, Kidani Y, Segiguchi M, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 1989; 43: 237–50

    Article  PubMed  Google Scholar 

  53. Mathè G, Chenu E, Bourut C. Experimental study of three platinum complexes: CDDP, CBDCA and 1-OHP on L1210 leukemia. Alternative or simultaneous association of two platinum complexes [abstract]. Invest New Drugs 1989; 7: 404

    Google Scholar 

  54. Extra JM, Marty M, Brienza S, et al. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998; 25 (2 Suppl. 5): 13–22

    PubMed  CAS  Google Scholar 

  55. Gamelin E, Le Bouil A, Boisdron-Celle M, et al. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin Cancer Res 1997; 3: 891–9

    PubMed  CAS  Google Scholar 

  56. Metzger G, Massari C, Renèe N, et al. Variations in platinum (Pt) plasma levels depending on chronomodulated oxaliplatin (1-OHP) peak time [abstract]. 33rd Proceedings of the American Society of Clinical Oncology (ASCO): 1997 May 17–20; Denver, 244

  57. Misset JL, Brienza S, Taamma A, et al. Pharmacokinetics, urinary and fecal excretion of ocaliplatin in cancer patients [ab-stract]. 87th Annual Meeting of the American Association for Cancer Research (AACR): 1996 Apr 20–24; Washington, 183

  58. Papamichael D, Joel SP, Seymour MT, et al. Pharmacokinetic interaction between 5-fluorouracil (%-FU) and oxaliplatin (L-OHP) [abstract]. Br J Cancer 1998; 78Suppl. 2: 12

    Google Scholar 

  59. Cailleux PE, Delva R, Boisdron-Celle M, et al. Influence of oxaliplatin on 5-fluorouracil pharmacokinetics; clinical consequences [abstract no. O56]. 8th International Congress on Anticancer Treatment; 1998 Feb 3–6; Texas

  60. Lokiec F, Wasserman E, Santoni J, et al. Pharmacokinetics (PK) of the irinotecan (CPT-11)/oxaliplatin (LOHP) combination: preliminary data of an ongoing phase I trial [abstract]. 88th Annual Meeting of the American Association for Cancer Research (AACR): 1997 Apr 12–16; San Diego, 76–7

  61. Figer A, Louvet C, Homerin A, et al. Analysis of prognostic factors of overall survival (OS) in the randomized trial of bimonthly leucovorin and 5-fluorouracil regimen (LV5FU2) with or without oxaliplatin (OXA) in advanced colorectal cancer (ACC) [abstract no. 918]. 35th Proceedings of the American Society of Clinical Oncology (ASCO): 1999 May 15–18; Atlanta, 239

  62. de Gramont A, Figer A, Seymour M, et al. A randomized trial of leucovorin (LV) and 5-fluorouracil (5FU) with or without oxaliplatin in advanced colorectal cancer (CRC) [abstract]. 34th Proceedings of the American Society of Clinical Oncology (ASCO): 1998 May 16–19; Los Angeles, 257

  63. Giachetti S, Brienza S, Focan C, et al. Contribution of second line oxaliplatin (OXA)-chronomodulated 5-fluorouracil-fo-linic acid (CM-5-FU-FA) and surgery to survival in metastatic colorectal cancer patients (MCC pts) [abstract no. 1050]. 34th Proceedings of the American Society of Clinical Oncology (ASCO): 1998 May 16–19; Los Angeles, 273

  64. Giacchetti S, Zidani R, Perpoint B, et al. Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (pts) with metastatic colorectal cancer (MCC) [abstract]. 33rd Proceedings of the American Society of Clinical Oncology (ASCO): 1997 May 17–20; Denver, 229

  65. Giacchetti S. Oxaliplatin: phase II/III trials in 1st line treatment of advanced colorectal cancer. Oxaliplatin in combination with 5-FU/folinic acid in untreated patients: results of a randomized phase III trial [abstract]. Col Cancer 1998: 61–70

    Google Scholar 

  66. Lèvi FA, Zidani R, Vannetzel J-M, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994; 86: 1608–17

    Article  PubMed  Google Scholar 

  67. Lèvi F, Zidani R, Misset J-L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997; 350: 681–6

    Article  PubMed  Google Scholar 

  68. Bècouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 1998; 16: 2739–44

    PubMed  Google Scholar 

  69. Díaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998; 105–8

    Google Scholar 

  70. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207–14

    Article  PubMed  CAS  Google Scholar 

  71. Seymour MT, Cassidy J, Wilson C, et al. Oxaliplatin 5-fluorouracil (FU) and folinic acid (FA) first-line combination therapy in colorectal cancer: results of a phase III trial [abstract]. Br J Cancer 1998; 78Suppl. 2: 21

    Google Scholar 

  72. Bertheault-Cvitkovic F, Jami A, Ithzaki M, et al. Biweekly intensified abmulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: 2950–8

    PubMed  CAS  Google Scholar 

  73. Gerard B, Bleiberg H, Van Daele D, et al. Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer. Anticancer Drugs 1998; 9: 301–5

    Article  PubMed  CAS  Google Scholar 

  74. Lèvi F, Misset J-L, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump: high antitumor effectiveness against metastatic colorectal cancer. Cancer 1992; 69: 893–900

    Article  PubMed  Google Scholar 

  75. Scheithauer W, Kornek GV, Raderer M, et al. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J Clin Oncol 1999; 17: 902–6

    PubMed  CAS  Google Scholar 

  76. deBraud F, Munzone E, Nolè F, et al. Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer wtih progressive disease while on or after 5-fluorouracil. Am J Clin Oncol 1998; 21: 279–83

    Article  PubMed  CAS  Google Scholar 

  77. de Gramont A, Tournigand C, Louvet C, et al. Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD [in French]. Rev Med Interne 1997; 18: 769–75

    Article  PubMed  Google Scholar 

  78. de Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high dose leucovorin and 5 fluorouracil 48 hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33: 214–9

    Article  PubMed  Google Scholar 

  79. Andre T, Louvet C, Raymond E, et al. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 1998; 9: 1–3

    Article  Google Scholar 

  80. Lèvi F, Perpoint B, Garufi C, et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer A 1993; 29A(9): 1280–4

    Article  PubMed  Google Scholar 

  81. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7: 95–8

    Article  PubMed  CAS  Google Scholar 

  82. Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509–20. Discussion 520-2

    Article  PubMed  CAS  Google Scholar 

  83. Bismuth H, Adam R. Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy. Semin Oncol 1998; 25 (2 Suppl. 5): 40–6

    PubMed  CAS  Google Scholar 

  84. Creekmore SP, Urba WJ, Longo DL. Principles of the clinical evaluation of biologic agents. In: De Vita VTJ, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer. Philadelphia (PA): Lippincott, 1991: 67–86

    Google Scholar 

  85. Misset J-L. Oxaliplatin in practice. Br J Cancer 1998; 77Suppl. 4: 4–7

    Article  PubMed  CAS  Google Scholar 

  86. Krikorian A, Vignoud J, Brienza S, et al. Oxaliplatin: global safety [abstract]. 5th International Congress on Anti-Cancer Chemotherapy: 1995 Jan 31- Feb 3; Paris, 257

  87. Bleiberg H. Colorectal cancer: the challenge. Eur J Cancer A 1996; 32ASuppl. 5: 2–6

    Article  Google Scholar 

  88. Sanofi. Eloxatine prescribing information. Paris: Sanofi, 1999

    Google Scholar 

  89. Tournigand C, Maindrault-Goebel F, Louvet C, et al. Severe anaphylactic reactions to oxaliplatin. Eur J Cancer A 1998; 34: 1297–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Lynda R. Wiseman, Julie C. Adkins, Greg L. Plosker & Karen L. Goa

Authors
  1. Lynda R. Wiseman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julie C. Adkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Greg L. Plosker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Karen L. Goa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lynda R. Wiseman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wiseman, L.R., Adkins, J.C., Plosker, G.L. et al. Oxaliplatin. Drugs & Aging 14, 459–475 (1999). https://doi.org/10.2165/00002512-199914060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199914060-00006

Keywords

Search

Navigation